I watched Dr Jay's excellent presentation. Thanks to those who posted the links. 39 helpful mintues if you own shares. His points were affirmed by the charmingly-accented UK more-than-30-years-in-research gentleman at the end. Try to imagine NP presenting to the NIH like that. Couldn't happen (but he tried hard).

Miles to go before we rest: dose-escalation and dose-optimization studies, just as a start. If I was young and feeling risky-frisky (but also patient, with a delayed gratification skillset (don't pick out your boat name yet)), this would be a very exciting new company to invest in. As an old guy who is 6 years in, there's excitement for you young bucks (and does), but also some sadness at the lost time (time equals lives here, imo). Dr J expressed the same, along with some trial design/design arm-wrestling regret (my own armchair: Why only two doses-day 0 and day 7? Why look at primary endpoint at day 28? Then day 42? Many of us wondered that.

Leronlimab works and will succeed. That's not speculation. Gotta go find my RANTES t-shirt. GLTA.